Hubei Longxiang Pharmaceutical Technology Co., Ltd. was founded in January 2008 with a registered capital of 122 million yuan. The controlling shareholder is Tianjin Ruipu Biotechnology Co., Ltd. (stock code: 300119). Longxiang Pharmaceutical was listed on the New Third Board in April 2017, with stock code: 871082. We currently have over 280 employees and total assets of 560 million yuan.

The company is a technology-based private enterprise engaged in the research and development, production, and sales of new safe veterinary drugs. It is one of the top ten production enterprises of animal raw materials in China, a national high-tech enterprise, an innovative enterprise in Hubei Province, a "specialized, refined, unique, and new small giant" enterprise in Hubei Province, a "first batch of agricultural science and technology innovation demonstration enterprises" in Hubei Province, a postdoctoral innovation base in Hubei Province, a hidden champion enterprise in the subdivision of pillar industries in Hubei Province, and a 4A level standardized good behavior enterprise. There is a provincially recognized "Hubei Province Engineering Technology Research Center for Veterinary Synthetic Raw Materials" and a Longxiang Pharmaceutical Wuhan R&D Center.

Longxiang Pharmaceutical attaches great importance to technological innovation work. The company has 13 national new veterinary drug certificates, 15 authorized invention patents, and 11 major scientific and technological achievements in Hubei Province. It has undertaken and completed 10 national and provincial major scientific and technological projects, and has won 6 provincial scientific and technological progress awards, including the Hubei Provincial Science and Technology Progress Award, Hubei Provincial Science and Technology Innovation Award for Small and Medium sized Enterprises, Hubei Provincial Science and Technology Achievement Promotion Award, and Hubei Provincial Invention Patent Excellence Award.

The integration of raw materials and preparations is the development strategy of the enterprise. The company currently has a production base for animal raw materials and preparations.

The new animal raw material drug production base is actively responding to the national call for "leaving the city and entering the park", and moved into the Makou Industrial Park in Wuxue Tian Town in 2021. The total investment is 600 million yuan, covering an area of 178 acres, with 14 raw material drug production lines and 6 synthesis workshops. The main products include florfenicol, trimethoprim, vonimilin, tocilizumab, oxalic acid, cephalosporin, etc. At the same time, several new second-class veterinary drugs such as montelukast, amikacin, and telmisartan will also be launched. After full production, the annual output value will be 600-800 million yuan.

The formulation production base is located in the old factory area of Wuxue Longping, covering an area of 128 acres. Currently, there are two production lines for powder and granule formulations. Among them, the flagship products include Flupheniramine Powder, Timiconazole Enteric coated Granules, Wonimilin Hydrochloride Premix, Flupheniramine Glucosamine Granules, etc. The annual output value is 200 million yuan.

To further extend and expand the industrial chain of raw materials and supporting formulations. The company plans to acquire 100 acres of land in the Makou Industrial Park of Tianzhen to construct the second phase of the raw material drug project, with a planned investment of 1 billion yuan. The main focus will be on building biological and chemical synthesis production lines, as well as automated formulation production lines. After completion, it is expected to achieve an annual output value of 3 billion yuan and provide more than 500 job opportunities.

Longxiang attaches great importance to product quality and adheres to the quality concept of "quality determines survival, quality wins trust". Multiple products have been successfully registered abroad. There are two main series of products: raw materials and formulations. 70% are raw materials and 30% are formulations. The company's raw material products are sold to domestic and international markets, with 49% exported. Multiple products have been successfully registered and sold in more than 30 developed countries and regions, including Germany, Belgium, Japan, Iran, Spain, Mexico, and South Korea; Longxiang is a major supplier of raw materials for the top 10 large pharmaceutical factories in China. The company's products are highly recognized by domestic and foreign users, with over 600 international and domestic customers. Having self operated import and export rights.

The company relies on its management team's profound industry experience, independent intellectual property rights, and the New Third Board platform to adhere to the dual wheel drive of endogenous growth and external expansion. Through various means such as equity, mergers and acquisitions, and strategic cooperation, it steadily develops. By 2024, the company's sales revenue will reach 1 billion yuan, total assets will exceed 1 billion yuan, and profits and taxes will each exceed 100 million yuan. Adhere to the path of continuous innovation and development, develop safe and low toxicity new veterinary drugs, wholeheartedly serve the animal husbandry industry, and build Longxiang Pharmaceutical into an innovative animal protection enterprise with high-quality new veterinary raw materials and characteristic preparations on a global scale.